Skip to content

Construction of the FGFs detection platform based on the novel SERS nanoprobe and its application in cardiovascular diseases

Construction of the FGFs detection platform based on the novel SERS nanoprobe and its application in cardiovascular diseases

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089047
Enrollment
Unknown
Registered
2024-08-30
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiocardiopathy

Interventions

Cardiovascular disease patients group:None

Sponsors

The 2nd Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Health volunteers Patients with cardiovascular disease: acute coronary artery syndrome, heart failure Criteria for acute coronary syndrome: (1) patients aged over 18 years old and younger than 75 years old; (2) a history of exertional chest pain or acute chest pain, but not more than 12h; (3) ECG ST segment depression in two or more adjacent leads, or elevation in limb leads 0.1 mV, thoracic leads 0.2 mV, or newly developed complete left (or right) bundle branch block; Criteria for heart failure: (1) patients older than 18 years old and younger than 75 years old; (2) Symptoms of dyspnea (3) NT-proBNP is greater than 450 pg/ml (less than 50 years), NT-proBNP is greater than 900 pg/ml (age 50-75 years), and NT-proBNP is greater than 180 pg/ml (more than 75 years) (4) Supported by the cardiac ultrasound evidence

Exclusion criteria

Exclusion criteria: (1) Previous history of intracranial hemorrhage or stroke in unknown parts, or previous ischemic stroke in the past 6 months; (2) Central nervous system injury, nervous system tumor or arteriovenous malformation; (3) Having experienced major trauma, surgical surgery or head injury in the past 2 months; (4) Gastrointestinal bleeding and hemorrhagic diseases with known causes in the past 1 month (except menstruation); (5) Clear, highly suspected or cannot exclude aortic dissection (1) has received a non-compression puncture procedure (such as liver biopsy, lumbar puncture procedure) within 24h; (6) In oral anticoagulant therapy; (7) 1 week of gestation or postpartum; (8) Refractory hypertension [systolic blood pressure> 180mmHg and (or) diastolic blood pressure> 110mmHg; (9) Advanced liver disease, infectious endocarditis, and active peptic ulcer; (10) Long-term or invasive recovery.

Design outcomes

Primary

MeasureTime frame
Fibroblast growth factor;

Countries

China

Contacts

Public ContactYan Fang

The 2nd Affiliated Hospital of Harbin Medical University

fangyan5668@163.com+86 138 3611 2917

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026